PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1455671
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1455671
Microbiome therapeutics Market size was valued at USD 102.45 Million in 2023, expanding at a CAGR of 36.78% from 2024 to 2032.
Microbiome therapeutics entail the development and application of treatments directed at the human microbiome, which comprises a complex community of microorganisms residing within the human body. These therapeutics are designed to restore, manipulate, or enhance microbial balance within the body, thereby fostering health and addressing various medical conditions. They manifest in different forms, including probiotics (live beneficial bacteria), prebiotics (substances promoting the growth of beneficial bacteria), postbiotics (metabolites produced by beneficial bacteria), and fecal microbiota transplantation (the transfer of fecal matter from a healthy donor to a recipient).
Microbiome therapeutics Market- Market Dynamics
Advancements in microbiome research to propel market demand
The majority of therapeutic agents in development are in the early stages, typically Phase I and Phase II. Regarding gastrointestinal (GI) indications, over 13 drugs out of 23 are under investigation, with the majority focusing on ulcerative colitis. For example, in 2021, Seres Therapeutics, Inc. introduced data from its Phase 3 ECOSPOR III study on SER-109, an oral therapy investigated for recurrent C. difficile infection, with an anticipated launch slated for the first half of 2023. Notably, compared to the placebo, SER-109 is associated with a decrease in antimicrobial resistance genes. Advancements in microbiome research are expected to facilitate the discovery of improved treatments for infections and other diseases, thereby enhancing medical care outcomes. To promote the adoption of microbiome-based treatments, companies are reducing the cost of their products and expanding access to cutting-edge medical care to a broader segment of the population. Additionally, several governing bodies are restructuring their approaches. Consequently, this presents market vendors with lucrative growth opportunities to enhance their market share.
Microbiome therapeutics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 36.78% over the forecast period (2024-2032)
Based on Product Type segmentation, FMT was predicted to show maximum market share in the year 2023
Based on Application segmentation, C. difficile was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Microbiome therapeutics Market is segmented on the basis of Product Type, Application, and Region.
The market is divided into two categories based on Product Type: FMT and Microbiome Drugs. In 2023, Fecal Microbiota Therapy (FMT) emerged as the dominant force in the microbiome therapeutics market. This dominance is primarily ascribed to its extensive utilization in treating C. difficile infection. Additionally, the growing focus on research and development aimed at exploring alternative therapeutic applications of FMT, coupled with the introduction of capsules into the market, is anticipated to propel its growth. For instance, in February 2021, OpenBiome announced the introduction of new direct testing for SARS-COV-2 in fecal microbiota therapy preparations, aiming to enhance FMT availability to scheduled patients for emergency use while mitigating the risk of infection transmission.
The market is divided into five categories based on Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes and Others. The application segment pertaining to Clostridium difficile infection (CDI or C. difficile) is forecasted to maintain dominance in the market in 2023. The expansion of this segment is attributed to the increasing adoption of Fecal Microbiota Transplants (FMT) for treating C. difficile infections. According to a 2020 study conducted by the University of Birmingham, FMT is widely accepted for treating patients afflicted with Clostridium difficile infections. Furthermore, FMT demonstrates greater efficacy in treating C. difficile compared to antibiotics, particularly in cases of recurrence.
Microbiome therapeutics Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Companies in the microbiome therapeutics market employ various strategies to stay competitive, including investing in research and development to explore new therapeutic applications, enhancing product accessibility and affordability, fostering collaborations with research institutions and healthcare providers, and leveraging technological advancements to improve product efficacy and safety. These strategies aim to drive innovation, expand market reach, and ultimately improve patient outcomes in the field of microbiome-based therapies.
In December 2021, Kaleido Biosciences revealed a partnership with Janssen to explore the efficacy of microbiome metabolic therapies in preventing immune, atopic, and metabolic conditions that emerge in childhood.
GLOBAL MICROBIOME THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
OpenBiome
Seres Therapeutics Inc.
4D Pharma plc.
Locus Biosciences, Inc.
Enterome SA
Finch Therapeutics Group, Inc.
Intralytix, Inc.
Microbiotica
Second Genome
Rebiotix Inc.
Vedanta Bioscience, Inc.
Others